The short interest data have been released for the December 30 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials.
These are five top new picks that the JPMorgan team likes this month. All make good sense for growth portfolios.
The December 15 short interest data have been compared with the previous figures, and short interest increased in most of these selected pharmaceutical stocks.
These are stocks that make good sense for investors looking to add to their overall equity holdings. They are all trading well below their 52-week highs and should be attracting substantial institutional…
For those looking to generate income, equities remain one of the best resources, and these five look like long-term winners.
With the top pharmaceutical stocks trailing the market by a large margin, they are starting to look very attractive for long-term growth and income investors.
In a recent research note, the analysts at Merrill Lynch make a big move by removing two blue chips from the firm's well-respected US 1 list of stocks to buy.
This trading week has been shorter than most with Thanksgiving taking place on Thursday. As a result not too many companies have released news, updates or earnings this week, despite the markets…
Eli Lilly & Co. (NYSE: LLY) is watching its shares in free fall on Wednesday, not from any election or political concerns but a late-stage trial failure. As we have said time…
Chris Lange Now is a good time to add quality stocks in front of what is usually a very good time of the year for equities. These four stocks offer investors solid upside potential.
The analysts at Merrill Lynch have made a big move by adding a top property and casualty company to the firm's well-respected US 1 list of stocks to Buy.
The recent headlines and the huge Trump following have helped closed the gap on Clinton, and if Trump is declared the winner, we could see a large market drop next week.
The relentless populist rhetoric has lowered the prices on some of the top pharmaceutical companies, and long-term growth and income investors have a chance to buy some great stocks on sale.
A UBS research report notes the segments of the economy that may disproportionately benefit as all the money that baby boomers had stashed away in savings, pensions, IRAs and 401(k) plans starts…
Eli Lilly plans to release its most recent earnings report before the markets open on Tuesday, and analysts expect top and bottom line growth.
Chris Lange 
